---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-25-000312"
form_type: "8-K"
ticker: "LNAI"
cik: "0001527728"
company_name: "Lunai Bioworks Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:00:51.405417+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Renovaro enters definitive merger with AI-driven Biosymetrics for 15M shares

## Summary
- Renovaro issues 15M unregistered common shares to Biosymetrics stockholders for all outstanding shares; lock-up of CEO shares for 1 year.
- 3M of the issued shares held in escrow for 1 year to satisfy potential indemnification claims.
- Merger expected to close by March 15, 2025, subject to Biosymetrics stockholder approval and Nasdaq listing.
- Biosymetrics' Elion AI platform has partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures.
- Combined entity to focus on AI-driven biomarker discovery and precision medicine in cancer and other diseases.

## SEC filing metadata
- accession: 0001731122-25-000312
- form_type: 8-K
- ticker: LNAI
- cik: 0001527728
- company_name: Lunai Bioworks Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527728/000173112225000312/0001731122-25-000312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527728/000173112225000312/e6390_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-25-000312
- JSON: https://secwatch.observer/filing/0001731122-25-000312.json
- Plain text: https://secwatch.observer/filing/0001731122-25-000312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.